Please assess the completion status of the following clinical trial:

Trial Title: Randomized Evaluation of Aggressive or Moderate Lipid Lowering Therapy With Pitavastatin in Coronary Artery Disease (REAL-CAD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who met following all criteria are entered in run-in period, loading pitavastatin 1 mg/day for more than 1 month when informed consent was given. (Primary registration)~* Coronary artery disease patients meeting one of the following events~  * History of Acute Coronary Syndrome (AMI or Unstable angina)~ * History of revascularization (PCI or CABG)~ * Diagnosis of ischemic heart disease and coronary artery stenosis as having 75% or higher stenosis according to the AHA classification~* Hypercholesterolemia patients meeting one of following criteria~  * LDL-C is 140 mg/dL or over~ * LDL-C is 100 mg/dL or over and requiring cholesterol lowering drugs judged by attending physicians~ * Patents receiving cholesterol lowering drugs~* Age (≧20 \<80 year-old)~* Patients given written informed consent.~Exclusion Criteria:~Exclusion Criteria(Pre-Run-in period)~* Patients planning revascularization~* Malignant tumor in active phase~* Patients who meet contraindication of LIVALO tablet below~  * Patients who have hypersensitivity to LIVALO tablet~ * Patients who have severe liver dysfunction or biliary atresia~ * Patients who are being treated with cyclosporine~ * Pregnant women, women suspected of being pregnant, or lactating women~* Patients who have heart failure NYHA III or greater~* Patients undergoing dialysis~* Patients with familial hypercholesterolemia~* Patients registered in the other clinical trials~* Patients taking prohibited drugs~* Patients who are ineligible in the opinion of the investigator~Exclusion Criteria(Post-Run-in period)~* LDL-C is 120mg/dL or over after Run-in period~* Patients with occurrence of acute coronary syndrome (AMI or Unstable angina) within 3 months~* Patients who have been undergone PCI or CABG within 3 months~* Compliance is less than 50% in Run-in period~* Patients who met primary endpoint in Run-in period.~* Patients who met adverse events in Run-in period and judged as ineligible in the opinion of the investigator~* Patients who are ineligible in the opinion of the investigator

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- Pitavastatin 1 mg daily (Type: ACTIVE_COMPARATOR): None
- Pitavastatin 4 mg daily (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).